Search /Find local listings
Locations/Canada/Retatrutide
Purchase and availability checkRetatrutide in Canada

Can you buy Retatrutide in Canada?

This page does not establish a legitimate retail purchase from the compound name or an online listing alone. Retatrutide is an investigational clinical program.

View exact 10 mg listing · CA$79.99 Direct answers →Open official records →Open the interactive status check
Evidence lane
Investigational clinical program
Destination
Canada
Source records
3
Reviewed
July 24, 2026
ByPeptide Local Editorial DeskUpdated July 24, 2026How we review
Regional catalog handoff

Compare current Retatrutide research listings for Canada.

This exact seller page states Canada market coverage. It is dated catalog observations, not proof of legal supply, contents, safety, or medical suitability.

Open clean public JSON
Market match
Canada
Current routes
1 of 1
Lowest observed
$8.00 / mg
Last checked
22 Aug 2026
ListingCurrent priceSource stateHandoff
Peptides Canada market boundary

Seller states Canada-only fulfillment, CAD 19.99 standard shipping below CAD 299.99, and typical delivery in under seven days after processing.

Operator check

The reviewed About and Terms pages do not identify a legal operator or business address. The seller explicitly states that public batch-specific COAs and laboratory reports are not available. This is a dated catalog observation, not an evidence or quality endorsement.

Exact seller-page observations for a declared country market. These rows are affiliate-supported source handoffs, not a provider ranking, medical recommendation, safety finding, legal-availability finding, or independent test of the listed material.

Direct answers

What this exact search can and cannot establish.

Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.

01

Can you buy Retatrutide in Canada?

This page does not establish a legitimate retail purchase from the compound name or an online listing alone. Retatrutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below. Before acting on an offer, match the exact product, authorization, seller identity, and supply route in the official records below.

02

Which official records should be checked for Retatrutide in Canada?

Resolve the exact identity of Retatrutide through TRIUMPH-1 Phase 3 study - NCT05929066 from ClinicalTrials.gov. Then search Drug Product Database from Health Canada for the destination product record and Choosing a safe online pharmacy from Health Canada for the seller, establishment, or supply route in Canada. A match in one record does not replace the other two checks.

03

Does an online listing prove Retatrutide is authorized or available in Canada?

No. A page using the name Retatrutide, local currency, a domestic delivery claim, or a familiar package image is only a lead. This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status. For Canada, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.

Live trial footprint

Retatrutide clinical trials in Canada

10 study records currently list 117 locations in this country, including 5 locations individually marked Recruiting.

Registry update: July 24, 2026
Study records
10
Listed locations
117
Recruiting locations
5
Records with local recruiting sites
1
NCT07165028
Study-wide statusRecruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Listed locations
15
Recruiting locations
5
Registry update
2026-07-17
NCT07035093
Study-wide statusActive, not recruiting

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Listed locations
5
Recruiting locations
0
Registry update
2026-07-23
NCT06383390
Study-wide statusActive, not recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Listed locations
22
Recruiting locations
0
Registry update
2026-07-20
NCT07357415
Study-wide statusActive, not recruiting

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Listed locations
10
Recruiting locations
0
Registry update
2026-06-09
NCT05929066
Study-wide statusCompleted

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Listed locations
9
Recruiting locations
0
Registry update
2026-06-03
NCT05882045
Study-wide statusActive, not recruiting

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Listed locations
17
Recruiting locations
0
Registry update
2026-05-22
Continue the exact comparison

Related country and compound records.

Compare another tracked name in Canada, or keep Retatrutide fixed and change the destination within North America. The identity, product, and seller checks remain separate.

Continue the exact comparison

Retatrutide in North America

Retatrutide across 42 countries
Identity before availability

A name alone cannot establish a local verdict.

Retatrutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.

Primary identity source: TRIUMPH-1 Phase 3 study - NCT05929066 / ClinicalTrials.gov ↗
Three-record verification path

Identity. Product. Seller or supply.

A credible result must keep these separate. The official links answer different questions and should be checked in sequence.

TRIUMPH-1 Phase 3 study - NCT05929066

TRIUMPH-1 Phase 3 study - NCT05929066 is maintained by ClinicalTrials.gov. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open TRIUMPH-1 Phase 3 study - NCT05929066 ↗

Drug Product Database

Drug Product Database is maintained by Health Canada. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Drug Product Database ↗

Choosing a safe online pharmacy

Choosing a safe online pharmacy is maintained by Health Canada. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Choosing a safe online pharmacy ↗
Canada / Country guide

Canada market context.

Health Canada warned in April 2026 that unauthorized injectable peptide drugs sold online can cause serious harm and said products labelled for research use should not be used as drugs.

  • Health Canada’s April 2026 advisory names BPC-157, GHK-Cu, MOTS-C, and other unauthorized injectable peptides among examples it seized.
  • The federal Drug Product Database can be searched by DIN, product, ingredient, company, status, route, and dosage form.
  • Pharmacy licensing is provincial or territorial, so a Canadian address must still be matched to the appropriate regulator’s public record.
Destination checklist

Repeat the country checks before comparing any offer.

The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.

01

Check the DIN

Authorized drugs sold in Canada carry an eight-digit Drug Identification Number that can be checked in Health Canada’s database.

02

Verify the pharmacy

Use the pharmacy regulatory authority for the province or territory where the business is established, including for online sellers.

03

Separate research labels

Do not treat a ‘research use only’ label, imported parcel, or wellness claim as a prescription or authorization pathway.

Primary evidence

Audit every source used by this page.

Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.

01
NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightClinicalTrials.gov
02
Drug Product DatabaseHealth Canada
03
Choosing a safe online pharmacyHealth Canada
04
What to know about retatrutideEli Lilly and Company
05
Unauthorized injectable peptide warningHealth Canada
06
Retatrutide study search in CanadaClinicalTrials.gov
07
NCT07165028: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)ClinicalTrials.gov
08
NCT07035093: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainClinicalTrials.gov
09
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)ClinicalTrials.gov
10
NCT07357415: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightClinicalTrials.gov
11
NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseClinicalTrials.gov
Audit and handoff

Keep the exact record attached.